A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)

NCT00152191 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1300

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: UFT (uracil, tegafur)
DRUG: cyclophosphamide, methotrexate, and fluorouracil

Sponsor

Taiho Pharmaceutical Co., Ltd.